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Biochemistry and Physiology of 
Gastrointestinal Somatostatin 
MICHAEL R. LUCEY and TADATAKA YAMADA 
Somatostatin, a tetradecapeptide initially isolated from the ovine hypothalamus, is widely 
distributed throughout the gastrointestinal tract where it may act as a hormone, local 
chemical messenger, or neurotransmitter to elicit many physiological actions. Release of  
somatostatin from D cells in the gut is regulated by mechanisms that are both dependent 
on and independent of  cAMP. In most cases somatostatin acts to inhibit the function of  
its target cells. It performs this action in part via pertussis-toxin-sensitive inhibitory 
guanine nucleotide-binding proteins that regulate adenylate cyclase activity. Other 
mechanisms may involve sites of  action distal to intracellular second messenger systems. 
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The story of the discovery and isolation of somato- 
statin is one in which an unexpected and unex- 
plained observation was pursued with great appli- 
cation to yield novel and far-reaching results. In 
1968, while searching for an hypothalamic growth 
hormone releasing factor, Krulich et al (1) found 
that fractions obtained on chromatography of sheep 
or rat hypothalamus had the effect of inhibiting 
growth hormone release from rat anterior pituitary. 
Subsequently, investigators in Guillemin's labora- 
tory made a similar observation, and they set out to 
identify the cause of this phenomenon. In the 
course of their labors they isolated from 500,000 
sheep hypothalami, a peptide we now call somato- 
statin-14 (S14), and by stepwise Edman degradation 
they determined its structure (2, 3). They described 
a 14-amino acid peptide with a cyclic conformation 
maintained by an intramolecular disulfide bond link- 
ing two cysteine residues (Figure 1). 
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This peptide inhibited release of growth hormone 
from somatotrophs. Following this advance, many 
other inhibitory actions of somatostatin were de- 
scribed. In 1975, Arimura et al (4, 5) described the 
first radioimmunoassay for somatostatin and, there- 
after the widespread distribution of somatostatin 
both within mammalian tissues and throughout the 
phylogena became clear. Somatostatin is present in 
virtually every tissue in the mammalian body, in all 
classes of vertebrate, in protochordate plants, pro- 
tozoa, and even prokaryotes. Four interrelated 
functions have been proposed for somatostatin in 
man--that of neurohumoral regulator, neurotrans- 
mitter, endocrine hormone, and paracrine hor- 
mone. 
This review will outline current understanding of 
the biochemistry, tissue distribution, release, and 
physiological function of gastrointestinal somato- 
statin and place particular emphasis on recent ad- 
vances concerning the cellular aspects of release 
and mechanism of action of somatostatin. 
STRUCTURE AND BIOSYNTHESIS 
Since its initial purification, somatostatin-14 (S 14) 
has been isolated and its amino acid sequence 
determined from a variety of species and tissues 
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Fig l .  Amino acid sequences of somatostatins (from reference 66). 
including porcine hypothalamus (6), anglerfish pan- 
creatic islets (7), guinea pig stomach and pancreas 
(8), catfish pancreas (9), and frog brain (10). Al- 
though when amino acid sequences are deduced 
from cloned mRNA in some species the possibility 
of variability in the S14 amino acid sequence has 
been raised, in fact all S14 identified to date have 
been identical to that originally described. This 
represents a remarkable degree of phylogenetic 
preservation. 
In 1978, Pradayrol et al (11) reported the purifi- 
cation and sequencing of a larger somatostatin 
isolated from porcine intestine. It consisted of 28 
amino acids ($28) and contained the S14 moiety at 
its carboxyl terminus linked to the first 12 amino 
acids by an Arg-Lys dipeptide (Figure 1). Subse- 
quent studies have shown that $28, in contrast to 
S14, can have considerable interspecies variation, 
especially when isolated from fish. $28 exerts many 
actions when administered in vivo and in vitro. 
While these are frequently of a similar nature to 
those of S14, there are considerable differences 
between the two moieties in specific actions, po- 
tency, and metabolism (see below). The relative 
importance of S14 and $28 as physiological effec- 
tors remains a subject of debate. 
By application of recombinant DNA technology, 
larger precursor forms of somatostatin comprising 
more than 100 amino acids have been discovered. 
These have been called preprosomatostatins.  
cDNAs encoding anglerfish (12), catfish (13), rat 
(14), and human preprosomatostatin (15) have been 
isolated and cloned. In each case $28 is found to 
occupy the carboxyl terminus. The presence of 
multiple mRNAs encoding somatostatin in an- 
glerfish and catfish pancreata is of particular inter- 
est, indicating that in submammalian species there 
may be expression of different genes for somato- 
statin within the same organ. The structural genes 
for human (16) and rat (17, 18) somatostatin have 
been cloned and are quite similar in overall confor- 
mation. 
Figure 2 describes some of the possible routes for 
posttranslational processing of somatostatin precur- 
sors to $28 and S14. It is uncertain whether in 
mammals $28 is formed first and then cleaved to 
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Fig 2. Alternative mechanisms for preprosomatostatin posttranslational processing (from reference 66). 
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S14 and a remnant peptide (2812) or whether $28 
and S 14 are each derived directly from larger pre- 
cursors. Not only is intraspecies variation in post- 
translational processing likely, but also within the 
same species, different tissues may process soma- 
tostatin precursors differently. This conclusion is 
strongly supported by the striking differences in 
distribution of S 14 and $28 throughout the mamma- 
lian gastrointestinal tract (see below). 
TISSUE DISTRIBUTION 
As stated above, somatostatin is almost ubiqui- 
tous in the mammalian body. The gastrointestinal 
tract and pancreas contain the greatest amounts of 
somatostatin. The majority of somatostatin in the 
human gut is confined to the mucosal layer where it 
is localized in endocrine cells, termed D cells. The 
remainder is present in neural cells, in which it 
forms part of the peptidergic neural system. In the 
stomach there are important differences between 
the D cells of the fundus and those of the antrum. 
Fundic D cells are of a "closed type," with no 
obvious luminal contacts; antral D cells are of an 
"open type,"  with their apical membrane exposed 
to the gastric lumen (19). As a consequence, it has 
been suggested that antral D cells respond to lumi- 
nal stimuli, whereas fundic D cells do not. Both 
fundic and antral D cells possess long cytoplasmic 
extensions that appear to abut on effector cells-- 
parietal and chief cells in the fundus, gastrin cells in 
the antrum (20-22). The presence of these cytoplas- 
mic extensions has been interpreted as evidence for 
a local or paracrine route of action for somatostatin. 
Duodenal D cells are typical flasklike endocrine 
cells with their apical membranes open to the intes- 
tinal lumen (21). In j ej unum and ileum, somatostatin 
is located most commonly in neurons (23, 24). 
There is little somatostatin in the colon. 
S14 is the predominant molecular form of soma- 
tostatin in the stomach, duodenum, and pancreas of 
rat and man (24-28). There is an increase in the 
relative proportion of $28 in the remainder of the 
small intestine. 
METABOLISM 
The half-life of S14 in plasma is extremely short, 
ranging from 0.5 to 3.0 min (29-35). In contrast, the 
plasma half-life of $28 has been found consistently 
to be two to five times longer (31, 33, 35). These 
results have led to confusion in estimating the 
relative potency of the two moieties. Many sites for 
degradation of somatostatin have been proposed, 
including liver (36, 37), pancreas (38), lungs (39), 
and kidneys (40). Recent studies have demonstrated 
rapid degradation of somatostatin by capillary ami- 
nopeptidases on isolated bovine brain microvessels 
(42) and also by aminopeptidase and endopeptidase 
activity on plasma membrane vesicles prepared 
from pig small intestine cells (42). These observa- 
tions provide a potential explanation for rapid me- 
tabolism of endogenous somatostatin released by 
brain neurotransmissions or from gut mucosa. The 
possibility of capillary peptidase activity in vessels 
outside the brain has not been studied. 
REGULATION OF SOMATOSTATIN RELEASE 
Elucidation of the mechanisms by which release 
of somatostatin is regulated has been confounded 
by a multitude of problems. When studied in vivo, 
measurement of somatostatin in plasma has posed 
many difficulties. Circulating plasma somatostatin 
is collected distant from the site of release and 
probably represents a mixture of somatostatin re- 
leased from many sources rather than from a single 
site. Conversely, since somatostatin is such an 
evanescent peptide and since it may be released for 
a paracrine action, circulating levels may remain 
unchanged in spite of significant local release. One 
response to these considerations is to study soma- 
tostatin release in an isolated organ preparation. 
However, even in such a system there may be 
regional variations in release within the organ or 
other uncontrolled and conflicting influences. Con- 
sequently isolated cellular preparations have 
proved particularly useful in elucidating both the 
intricate balance of controls that order somatostatin 
release and the intracellular mechanisms by which 
these controls are exercised. 
Table 1 lists some of the factors shown to influ- 
ence gastrointestinal somatostatin release in vari- 
ous models. Somatostatin release in response to 
luminal stimuli is of particular interest. Many stud- 
ies in animals and man have shown that luminal 
nutrients, fat, and protein in particular, almost 
invariably release somatostatin into portal blood or 
peripheral circulation (43-47). Both S 14 and $28 are 
released. The sites of release are probably gastric 
and duodenal, while in the intact dog at least the 
pancreas does not appear to contribute (48). The 
mechanisms by which nutrients initiate or sustain 
somatostatin release have not been elucidated well. 
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TABLE 1. SUMMARY OF AGENTS THAT INFLUENCE GASTRIC 
SOMATOSTATIN RELEASE* 
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*From reference 66. 
One possibility is that nutrients stimulate acid 
secretion, which in turn stimulates somatostatin 
release. Since somatostatin may act as an inhibitor 
of acid secretion, this would constitute a negative- 
feedback loop. However, although acid in many 
circumstances can stimulate somatostatin secretion 
(49, 50), this is not invariable (51). Since neutral 
solutions of nutrients can stimulate somatostatin 
release in antrectomized dogs (43), it is likely that 
nutrients can stimulate somatostatin independently 
of acid secretion. Thus the physiological impor- 
tance of luminal acidity in somatostatin release is 
uncertain. 
Somatostatin release stimulated by luminal nutri- 
ents is under neural control. However, in vivo and 
in vitro studies directed at defining these neural 
influences have yielded conflicting results. For ex- 
ample, in man and in intact dogs (52, 53), vagal tone 
appears to facilitate somatostatin secretion, while in 
intact cats (54), in isolated stomach, and isolated 
pancreas preparations cholinergic agonists are in- 
hibitory (55-58). Similar conflicts are found with 
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other neuropharmacologic agonists and antago- 
nists. 
Studies using an isolated cell culture system have 
allowed careful dissection of some of these influ- 
ences. This technique achieves an enriched primary 
culture of somatostatin cells derived from canine 
fundic mucosal cells (59, 60). Canine fundic muco- 
sal cells are dispersed with collagenase and then 
separated with counterflow elutriation. Following 
this process, somatostatin cells comprise about 9% 
of total cells in the small cell fractions and are 
separated completely from parietal cells and par- 
tially from chief and mucosa cells. Mast cells and 
other endocrine cells are also present. These small 
cell fractions are then plated onto collagen and 
maintained in primary culture for two days, after 
which somatostatin cells comprise 70 -+ 6% of 
cultured cells. These cells can then be subjected to 
short-term incubation with neuropharmacologic 
agents and somatostatin release estimated. 
Using this primary culture of enriched canine 
fundic D cells, at least two stimulatory pathways for 
somatostatin have been defined (59-63): a cAMP- 
dependent system and a cAMP-independent system 
(Figure 3). The cAMP-independent pathway may 
involve membrane phosphoinositide turnover and/ 
or intracellular protein kinase C activation. It is 
partially dependent on extracellular calcium but 
appears to be unaffected by specific antagonists of 
membrane calcium channels or calmodulin. Epi- 
nephrine and beta-adrenergic agonists activate the 
cAMP-dependent system. Gastrin, CCK, and TPA 
(12-O-tetradecanoylphorbol-13-acetate, a phorbol 
ester that interacts directly with protein kinase C) 
activate the cAMP-independent pathway. It is of 
interest that CCK, on a molar basis, is a more 
potent stimulus of somatostatin release by these 
primary cultures than gastrin, although this greater 
potency does not correspond to great receptor 
affinity (61). 
The inhibitory control of somatostatin release 
from primary cultures of enriched canine fundic D 
cells is complex. Under standard conditions carba- 
chol reduces both basal and stimulated somato- 
statin release (60). The focus for this action appears 
to be distal to "second messengers," since carba- 
chol inhibits the response to a diverse set of stimuli 
including epinephrine, dibutyryl cAMP, forskolin, 
gastrin, or TPA. It is curious, however, that while 
carbachol induces cAMP production, concomi- 
tantly it induces an increase in the indices of mem- 
brane inositol phospholipid turnover (63-65). These 
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Fig 3. Intracellular mechanisms governing somatostatin release. CCK, cholecystoki- 
nin; DAG, diacylglycerol; IP3, inositol triphosphate; PIP2, phosphatidylinositol-4,5- 
bisphosphate (fi'om reference 66). 
conflicting observations were reconciled after fur- 
ther studies in which primary cultures of fundic D 
cells were pretreated with pertussis toxin prior to 
administration of carbachol. Pertussis toxin binds 
inhibitory guanine nucleotide-binding proteins reg- 
ulating adenylate cyclase activity. Following per- 
tussis toxin pretreatment, carbachol had a stimula- 
tory effect on basal somatostatin release and 
potentiated the stimulatory response to forskolin 
(64). Pretreatment with pertussis toxin abolished 
the carbachol-induced decrease in cAMP produc- 
tion, but the increase in membrane inositol phos- 
pholipid turnover was unchanged. Atropine re- 
versed all effects of carbachol in pertussis-toxin- 
pretreated D cells. These data suggest that in pri- 
mary cultures of enriched canine fundic D cells 
carbachol interacts with a surface muscarinic recep- 
tor to have dual but contrary effects via separate 
intracellular mechanisms. First there is an inhibi- 
tory effect that is dependent in part on regulation of 
cAMP and that incorporates a pertussis-toxin- 
sensitive guanine nucleotide-binding protein. This 
action is dominant and only when it is inhibited by 
pretreatment with pertussis toxin is a second, albeit 
stimulatory, action of carbachol revealed. The sti- 
mulatory effect is complex and probably is not 
solely dependent on increases in membrane phos- 
phoinositide turnover since carbachol, in the pres- 
ence ofpertussis toxin, can potentiate the release of 
somatostatin induced by gastrin without further 
enhancing phosphoinositide turnover (65). 
ACTIONS OF SOMATOSTATIN IN THE GUT 
A recurring problem in estimating the actions of 
somatostatin has been an inability to distinguish 
between physiological and pharmacological effects. 
While it is relatively easy to mimic physiological 
plasma concentrations of somatostatin, appropriate 
doses to mimic paracrine concentrations are rarely, 
if ever, known. It is possible that grossly pharma- 
cologic doses of somatostatin yield concentrations 
that are physiologic at the cell surface. 
Table 2 lists the proposed functions of endoge- 
nous somatostatin in the gastrointestinal tract. 
These have recently been reviewed (66). The action 
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TABLE 2. BIOLOGICAL ACTIONS OF SOMATOSTATIN IN THE GUT* 












Inhibition of neuroendocrine secretion 
Gastrointestinal tract--gastrin, CCK, secretin, VIP, GIP, 
motilin, gut glucagon, EGF, acetylcholine 
Pancreas~insulin, glucagon, pancreatic polypeptide 
Motility 
Inhibition 
late phase of gastric emptying 
gastric MMCs 
gallbladder contraction 
ileal longitudinal muscle contraction 
Stimulation 




secretion of fluid and bicarbonate 
absorption of calcium, glucose, glucatose, glycerol, 
fructose, xylose, lactose, amino acids, triglycerides 
Miscellaneous 
Inhibition of splanchnic blood flow 
Inhibition of tissue growth and proliferation 
Food intake 
stimulation in fasted animals 
inhibition in fed animals 
*From reference 66. 
of gut somatostatin that has received most attention 
is regulation of acid secretion. In both dogs (33) and 
man (45) in vivo it has been shown that a physio- 
logical increase in plasma somatostatin concentra- 
tion, such as occurs postprandially, can result in 
reduction in acid secretion. This occurs without an 
alteration in plasma gastrin concentration. This 
suggests that somatostatin may circulate to act as 
an endocrine regulator of acid secretion. In the dog 
S14 is 10 times as potent an inhibitor of acid secretion 
as $28 (33). This became clear only after their dif- 
ferent rates of metabolism were taken into consider- 
ation and their respective potencies examined as a 
function of incremental plasma concentration. 
Recently Seal et al (67) have shown in rats with a 
gastric fistula that intravenous administration of a 
specific monoclonal antisomatostatin antibody can 
reverse the inhibitory action of intraduodenal infu- 
sion of oleic acid on meal-stimulated gastric acid 
secretion. This suggests that the acid inhibitory 
action of intraduodenal fat (so-called enteroga- 
strone effect) is at least in part a consequence of the 
action of endogenous somatostatin. Whether this is 
an endocrine or paracrine phenomenon needs fur- 
ther study. 
As noted earlier in this review, the morphology of 
gastric D cells with long cytoplasmic processes 
abutting onto local effector cells suggests a para- 
crine role for gastric somatostatin. Short et al (68) 
have reported that perfusion of an isolated rat 
stomach with antisomatostatin antibody enhanced 
acid secretion. Thus, locally released somatostatin 
may be acting as a restraint on acid secretion. 
There are many mechanisms by which somato- 
statin might reduce acid secretion. As shown in 
Table 3, these include direct action on the parietal 
cell, inhibition of gastrin release, increased produc- 
tion of prostaglandins, and reduction in mucosal 
blood flow. It is most likely that somatostatin pro- 
duces its effect on acid secretion by a combination 
of actions. 
The advent of stable somatostatin analogs for use 
as radioligands has allowed demonstration of sur- 
face receptors for somatostatin on isolated enriched 
canine parietal cells in short-term culture (69). In 
this model, binding affinity closely parallels the 
inhibitory potency of the peptide. However, the 
equal potency of S14 and $28 observed in this 
model is in sharp contrast to the markedly greater 
potency of S14 compared to $28 in vivo. This 
suggests that indirect influences may be of great 
importance in determining the acid inhibitory action 
of circulating somatostatin. Although there are dif- 
ferences in their data, both Park et al (69) and Chew 
(70) have been able to demonstrate a direct effect of 
somatostatin on function in isolated parietal cells. 
The influence of somatostatin, if any, on gastrin 
secretion is most likely to be paracrine since plasma 
concentrations of somatostatin sufficient to inhibit 
TABLE 3. MECHANISMS OF SOMATOSTATIN-INDUCED ACID INHIBITION* 
Receptor ? ? Gastrin cell 
Effects $ Blood flow t Prostaglandin ~, Gastrin release 
02 $ Histamine effect $ Stimulation 




Postkinase activation action 
*From reference 66. 
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acid secretion completely had no effect on serum 
gastrin. The morphology of D cells in the antrum 
supports this mechanism of action. Much work has 
been directed at defining the exact interrelationship 
of gastrin and somatostatin. In many instances the 
secretion of the two peptides appears reciprocal, 
demonstrating a so-called functional linkage, but 
this is not invariable. Nonetheless, local regulation 
of gastrin by somatostatin appears probable. 
CELLULAR BASIS OF SOMATOSTATIN 
ACTION 
In order to consider the cellular mechanisms by 
which somatostatin exerts its actions, one must 
frequently extrapolate from studies in nongastroin- 
testinal systems. These studies, as well as studies in 
cells of gastrointestinal origin, suggest that somato- 
statin may have many effects. Somatostatin has 
been shown to interfere with cAMP production in 
primary cultures of enriched parietal cells through 
inhibition of adenylate cyclase (69). This action 
(and some others described below) may require 
interaction with a membrane-associated guanine 
nucleotide regulatory protein. Somatostatin may 
also inhibit parietal cell function by interfering 
with a cAMP-related pathway at a point distal to 
cAMP production or through cAMP-independent 
mechanisms (69). In nongastrointestinal D cells it 
has been proposed that this pathway is also related 
to a membrane-associated pertussis-toxin-sen- 
sitive guanine nucleotide-regulating protein (71). 
There are conflicting data regarding the role of 
intracellular calcium fluxes in modulating the 
cAMP-independent pathway. Somatostatin may 
act through a more nonselective mechanism such 
as that proposed by Reyl and Lewin (72), who 
showed that the intracellular binding site for so- 
matostatin in gastric mucosa may be a phospho- 
protein phosphatase. It has been suggested that 
somatostatin alters membrane-related events, 
such as dephosphorylating membrane proteins 
(73), or alters the final exocytic process (74). By 
whatever mechanism somatostatin acts, its phys- 
iological importance as a regulator of many pro- 
cesses in the body is profound. The potential 
usefulness of an analog of this interesting hormone 
in therapy of a variety of human pathological 
conditions will soon be explored. 
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